Guangzhou, December 6th, 2018 – Guangzhou Wondfo Biotech Co., Ltd has received the prequalification (PQ) notification from the World Health Organization (WHO). Wondfo HIV testing products are prequalified by WHO and will be listed in WHO’s recommended in vitro diagnosis (IVD) products.
The WHO established a prequalification mechanism in 2001 regarding medicines against malaria and tuberculous. In later years, WHO continued to include more medicines and testers in its PQ range, such as medicines against reproductive diseases, affluenza, bacteria, and zinc products, APIs, vaccines and rapid diagnosis testers (RDTs).
Products with WHO PQ will be qualified as objects for United Nations’ official bulk purchase. It is also an important entrance standard of international NGOs regarding medicines and IVD products purchasing.
The world has recorded 36.9 million AIDS carriers at the end of 2017. Based on the purchasing data from Global Fund, the global support fund for prevention and control against AIDS and malaria valued 25 billion USD. AIDS prevention and control took 17 million USD. The 200 million USD spent annually on purchasing HIV testing cards are mainly from NGOs like the WHO, the UNICEF, the Global Fund, the Bill & Melinda Gates Foundation, for use in Africa and Southeast Asia.
Wondfo, having launched its first HIV RDTs in 2006, has now covered fields like HIV Blood/Serum/Plasma test. Its products are known for stable quality and simple processes to use, with results to be obtained as fast as in 15 minutes. In over a decade of development and expansion, Wondfo HIV testers have served more than 100 countries and regions in Asia, Africa and Latin America.
The PQ certification from WHO has qualified Wondfo as a supplier in the international NGO purchase market, powering its market development in Africa and Southeast Asia. Wondfo will not cease its endeavor in providing high-quality simultaneous diagnosis products and services in the global fight against HIV.